Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 194

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 194
---
 to manufacturing processes or third-party contractors that may be necessary or desired could result in other delays; |

| • |     | Kineta may experience import delays of its product candidates manufactured abroad; |

| • |     | Kineta or its third-party contractors may experience delays due to complications associated with pandemics or other health crises; |

| • |     | the cost of preclinical testing and studies and clinical trials of any product candidates may be greater than Kineta anticipates or greater than Kineta’s available financial resources; |

| • |     | the supply or quality of Kineta’s product candidates or other materials necessary to conduct clinical trials of its product candidates may be insufficient or inadequate or Kineta may not be able to obtain sufficient quantities of combination therapies for use in clinical trials; |

| • |     | reports may arise from preclinical or clinical testing of other cancer therapies that raise safety or efficacy concerns about Kineta’s product candidates; and |

| • |     | regulators may revise the requirements for approving Kineta’s product candidates, or such requirements may not be as Kineta anticipates. |

If Kineta is required to conduct additional clinical trials or other testing of its product candidates beyond the clinical trials and testing that Kineta contemplates, if Kineta is unable to successfully complete clinical trials or 114

other testing of its product candidates, if the results of these clinical trials or tests are unfavorable or are only modestly favorable, or if there are safety concerns associated with any of product candidates, Kineta may:

| • |     | incur additional unplanned costs; |

| • |     | be required to suspend or terminate ongoing clinical trials; |

| • |     | be delayed in obtaining marketing approval, if at all; |

| • |     | obtain approval for indications or patient populations that are not as broad as intended or desired; |

| • |     | obtain approval with labeling that includes significant use or distribution restrictions or safety warnings or be subject to the addition of labeling statements, such as warnings or contraindications; |

| • |     | be subject to additional post-marketing testing or other requirements; |

| • |     | be required to perform additional clinical trials to support approval; |

| • |     | have regulatory authorities withdraw or suspend their approval of the drug or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation strategy (“REMS”); |

| • |     | have the product removed from the market after obtaining marketing approval; |

| • |     |